MJA 217 1 4 July cover

Issues

Volume 217 Issue 1

4 July 2022

News

4 July 2022 Free

News briefs

Testosterone replacement therapy not associated with higher heart risks Testosterone replacement therapy appears safe in the short‐to‐medium term to treat hypogonadism, according to an analysis of the treatment, published in The Lancet Healthy Longevity. Researchers from the University of Melbourne and the University of Aberdeen conducted a systematic review identifying 35 eligible clinical trials published since 1992, of which 17 provided individual participant data. A blinded analysis by two independent clinicians enabled the classification of every cardiovascular event, allowing for a more robust analysis of the cardiovascular safety of testosterone treatment. The researchers performed a meta‐analysis using individual participant data from 17 studies and a further meta‐analysis integrating these data with the aggregate data provided by the 18 trials that did not provide individual participant data. Among the 17 trials with individual patient data, 1750 participants received testosterone and 1681 were given a placebo. The average length of testosterone treatment was 9.5 months. The average age of participants was 65years, and most were white and did not smoke. Participants’ average BMI was 30kg/m2, which is considered obese. A meta‐analysis showed there were 120/1601 (7.5%) cardiovascular events in the testosterone group and 110/1519 (7.2%) in the placebo group across 13 trials that provided this information. Patient age, smoking or diabetes status did not affect cardiovascular risk. Similarly, there was no significant difference in mortality rate between the testosterone group (6/1621 deaths, 0.4%) and the placebo group (12/1537 deaths, 0.8%) across the 14 trials that provided individual patient data on mortality, but only limited data were available. Testosterone significantly reduced serum total cholesterol, high density lipoprotein, and triglyceride levels compared with placebo. However, there were no significant differences in serum low density lipoprotein, blood pressure, glycaemic parameters, diabetes incidence, and prostate adverse outcomes between the testosterone and placebo groups. https://www.thelancet.com/journals/lanhl/article/PIIS2666‐7568(22)00096‐4/fulltext Inconsistent sleep associated with hypertension risk A Flinders University study, published in Sleep, of more than two million nights of sleep and blood pressure data found that irregularities in sleep timing and duration were associated with an increased risk of hypertension. Results showed that high sleep duration irregularity was associated with a 9% to 15% increase in hypertension risk. Furthermore, a 38‐minute increase in sleep midpoint irregularity was associated with an 11% risk increase, and a 31‐minute increase in sleep onset time irregularity was associated with a 29% increased risk of hypertension. The researchers analysed data collected over 9 months from 12300 participants who were aged between 18 and 90years. Metrics were recorded with an under‐mattress sleep device and a portable blood pressure monitor. Sleep duration regularity was assessed as the standard deviation via device‐assessed total sleep time. Sleep timing regularity was assessed as the standard deviation in sleep onset time and in sleep midpoint. Logistic regressions controlling for age, sex, body mass index, and mean total sleep time were conducted to investigate potential associations between sleep regularity and hypertension, which was found in 2499 participants. “These new insights into the potential adverse impact of irregular sleep timing and duration on heart health further highlight the importance of the role synchronising the body clock and prioritising enough sleep opportunity for optimal health and wellbeing,” said senior author Professor Danny Eckert, Director of the Adelaide Institute for Sleep Health. https://academic.oup.com/sleep/article/45/Supplement_1/A93/6592269

Perspectives

Indigenous health 4 July 2022 Open Access

The need for a roadmap to guide actions for Aboriginal and Torres Strait Islander adolescent health: youth governance as an essential foundation

The current lack of a national strategy for Indigenous adolescent health in Australia is a glaring gap

Seth Westhead · Quinton Appleby · Brittney Andrews · Tina Brodie · Alex Brown · Karla Canuto · Josh Cooke · Mahlia Garay · Thomas Harrington · Djai Hunter · Corey Kennedy · Jaeda Lenoy · Olivia Lester · Hannah McCleary · Odette Pearson · Lorraine Randall · Rachel Reilly · Hamish Rose · Daniel Rosendale · Jakirah Telfer · Peter Azzopardi

Medical education

Media review

Editorials

Research

Study protocols

Environmental health 4 July 2022 Open Access

SISTAQUIT: training health care providers to help pregnant Aboriginal and Torres Strait Islander women quit smoking. A cluster randomised controlled trial

Our multicomponent intervention is a highly translatable primary care approach to reducing smoking by pregnant Indigenous women

Gillian S Gould · Nicole M Ryan · Ratika Kumar · Leah C Stevenson · Kristin V Carson‐Chahhoud · Christopher Oldmeadow · Joley Foster · Simon Deeming · Katherine Boydell · Christopher M Doran · Andrew Searles · Joerg Mattes · Louise Atkins · Marilyn Clarke

Research letters

Indigenous health 13 June 2022 Free

Value of single troponin values in the emergency department for excluding acute myocardial infarction in Aboriginal and Torres Strait Islander people

Aboriginal and Torres Strait Islander people may benefit from culturally appropriate cardiac risk factor management

Jaimi H Greenslade · Sara Berndt · Laura Stephensen · Katrina Starmer · Greg Starmer · William Parsonage · Victor Lau · Tileah Drahm‐Butler · Tania Davis · Virginia Campbell · Richard Stone · Robert Bonnin · Sarah Ashover · Tanya Milburn · Elizabeth Mowatt · Karlie Proctor · Anthony Brazzale · Louise Ann Cullen

Narrative review

Indigenous health 4 July 2022 Open Access

Interrogating the intentions for Aboriginal and Torres Strait Islander health: a narrative review of research outputs since the introduction of Closing the Gap

We need intellectual investment that prioritises Indigenous ways of knowing, being and doing, and acknowledges the historical and contemporary colonisation, dispossession and racism that continue to have an impact on health outcomes today

Michelle Kennedy · Jessica Bennett · Sian Maidment · Catherine Chamberlain · Kate Booth · Romany McGuffog · Bree Hobden · Lisa J Whop · Jamie Bryant

Letters

Infectious diseases 4 July 2022 Free

Skin health situational analysis to inform skin disease control programs for the Kimberley

To the Editor: The impetigo burden for Australian Aboriginal children living in remote areas is the highest in the world, affecting 45% at any one time.1 This unacceptable public health crisis contributes to ongoing high rates of rheumatic fever and glomerulonephritis, both sequelae of Streptococcus pyogenes or group A streptococcus (GAS) infection.2 GAS infection is the key immediate driver of impetigo.3 Colonisation, social determinants and inadequate housing are overarching drivers.4 To reduce the skin infection burden, the See, Treat, Prevent (SToP) Trial (registered with the Australian New Zealand Clinical Trials Registry, ACTRN12618000520235) was funded as a stepped wedge, cluster randomised trial in partnership with Aboriginal service providers and communities to see, treat and prevent skin infections.1 Before commencing, a situational analysis5 was performed in 2017 to describe trends, driving forces and conditions related to skin infections. The situational analysis5 identified the complex, courageous yet under‐resourced environmental health and health promotion activities in the Kimberley that could be included as prevention aspects in the SToP Trial1 and found: • a well established program of health advocacy and collaboration integrating public and environmental health which prioritises prevention; • remote Aboriginal populations remain relatively stable with predictable mobility between communities, in contrast to the high turnover of the predominantly non‐Aboriginal health workforce; and • access to household maintenance throughout Kimberley communities, necessary to prevent skin infections, remains limited and frequently under‐resourced. Despite this need, the resourcing required for this sector to deliver on these services has not occurred.6 Before the SToP Trial, prior skin infection studies focused on biomedical treatments as short term solutions to improve skin health.1 Integration of diagnosis, treatment and prevention activities in a single trial to inform skin disease control is novel and needful. Aboriginal communities and health care organisations highlighted the urgent need to incorporate prevention to reduce the inequitable burden of skin infections. The key findings of the situational analysis are as follows:5 • services are working together to combat the high burden of skin infections in the Kimberley; • the immediate environment continues to contribute to poor skin health and is an area for intervention; • addressing the social determinants of health is critical to reducing skin infections; • partnerships are required to appropriately achieve the healthy living practices; and • the Kimberley has led the way with the development of the environmental health referral form. The SToP Trial includes clinic and school staff training modules for the identification and treatment of skin infections. These include online options to overcome the logistic challenges limiting face‐to‐face professional development in isolated locations and to support continuous training of new staff. The stability of the community is a strength and community requests have led to the incorporation of family training packages. Partnerships between primary health care and environmental health service providers are allowing for the better integration of prevention measures within communities. Capitalising on the advocacy and collaboration demonstrated by Aboriginal leaders across the region has aided SToP Trial initiatives, with results expected in 2023.

Frieda McLoughlin · Vicki O’Donnell · Asha C Bowen

Environmental health 4 July 2022 Free

Congenital syphilis on the rise: the importance of testing and recognition

To the Editor: Wu and colleagues1 describe a case of congenital syphilis where the mother had no apparent risk factors and a single negative syphilis serology collected in early pregnancy. The father had an identifiable risk factor. In metropolitan Perth, Western Australia, infectious syphilis among women of reproductive age is rising, with an over 18‐fold increase from 2015 to 2021 (Box). During this period, most cases (229, 74.1%) were non‐Indigenous women. This growth has been accompanied by cases in pregnancy and, concerningly, neonates with congenital syphilis. The authors1 observed that identifying risk factors during pregnancy is challenging. They may be absent, difficult to ascertain, subject to change during the pregnancy, and are dependent on the pregnant woman and her sexual partners, whose risks she may not know. Identification relies on health care providers checking the risk throughout pregnancy and on whether the woman recognises, discloses or feels safe to discuss a risk factor. In Perth, syphilis diagnoses among pregnant women are occurring across cultural backgrounds. While some women have additional risks such as insecure housing or illicit drug use, this is not the norm. Consequently, and because we have likewise observed neonates with congenital syphilis born to women who screened negative early in pregnancy, routine syphilis serology at initial visit and at 28 and 36weeks (or delivery, if earlier) is now recommended for all pregnant women in metropolitan Perth as per the WA sexual health guidelines2 and local obstetric guidelines.3 This was achieved through the collaboration of clinical and public health staff under the Antenatal and Postnatal Working Group of the WA Syphilis Outbreak Response Group, where a decision was made that monitoring risk factors throughout pregnancy has limitations. Three‐test syphilis screening for all pregnant women minimises the risk of congenital syphilis occurring because of an unrecognised risk factor, ensures emerging risk factors are not missed, helps normalise testing and reduce stigma, and recognises that women remain sexually active while pregnant. Notably, screening is not a replacement for good history taking and clinical examination, but syphilis can present in subtle and unusual ways that can be overlooked. Routine syphilis testing at the first antenatal visit is advised by the Australian sexually transmissible infections guidelines.4 A test early in the third trimester is recommended depending on local guidelines.4 As syphilis rates grow in many parts of Australia,5 other jurisdictions should consider adopting additional routine syphilis screening for all pregnant women. Box – Infectious syphilis cases among women of reproductive age, 2015–2021 Data sources: The number of cases were obtained from the Western Australian Notifiable Infectious Diseases Database, Department of Health Western Australia (Jan 2022); and the rate of cases were obtained from the Australian Bureau of Statistics census‐derived population data from the Epidemiology Branch, Public and Aboriginal Health Division, Western Australia Department of Health (Dec 2021).

Hannah MacKenzie · Suzanne McEvoy · Michelle Porter

Women's health 4 July 2022 Free

Unintended pregnancy among Aboriginal and Torres Strait Islander women: where are the data?

To the Editor: In Australia, up to 40% of women have experienced an unintended pregnancy,1 which can be associated with suboptimal pre‐conception health behaviour and reproductive health care engagement and adverse maternal and neonatal outcomes.1 Aboriginal and Torres Strait Islander women experience higher rates of pregnancy risk factors, adverse perinatal outcomes, and adolescent pregnancy compared with non‐Indigenous women.2 However, little is known about the prevalence and impact of unintended pregnancy among Aboriginal and Torres Strait Islander women. While two related national studies have been undertaken over the past decade, Aboriginal and Torres Strait Islander people were underrepresented1 or Indigeneity was unreported.3 Access to sexual and reproductive health care is a government priority,4 but without adequate data, dealing with issues or evaluating change will be impossible. This knowledge gap must be addressed. We need to better understand the prevalence, experiences and outcomes of unintended pregnancy for Aboriginal and Torres Strait Islander people (acknowledging that unintended does not necessarily mean unwanted), including issues relating to pregnancy intentions, decision making, and health care access. Meaningful engagement and collaboration with Aboriginal and Torres Strait Islander communities and researchers are required to confirm priority issues, design culturally appropriate data collection processes, and achieve a nationally representative sample. Data sources such as those held by primary health care providers and Aboriginal Community Controlled Organisations have an untapped potential to highlight the needs and priorities of Aboriginal and Torres Strait Islander people, should they be used with appropriate consultation and respect for Indigenous data sovereignty. Furthermore, knowledge gained must inform the national policy gap that exists in the area of holistic reproductive health. A national reproductive health policy and an implementation plan that address unintended pregnancy, decision making and management are urgently needed. These must be developed with due consideration to the needs of Aboriginal and Torres Strait Islander peoples from a strengths‐based paradigm and a decolonising approach that recognises historical reproductive rights violations.5 Data collection within a supportive policy framework will inform service provision, education and health promotion initiatives to improve maternal and infant outcomes and support Aboriginal and Torres Strait Islander women and families in choosing whether and when they have children.

Jessica Botfield · Emma Griffiths · Faye McMillan · Danielle Mazza

Next Issue Volume 217 Issue 2

View more
MJA 217 2 18 July cover
News 18 July 2022 Free

News briefs

Perspectives 18 July 2022 Open Access

Clinical gene technology in Australia: building on solid foundations

Gabrielle O'Sullivan · Joshua G Philips · John EJ Rasko

Perspectives 4 July 2022 Free

mRNA vaccines: a transformative technology with applications beyond COVID‐19

Isabella Overmars · George Au‐Yeung · Terence M Nolan · Andrew C Steer

Medical education 18 July 2022 Lessons from practice Open Access

Cutaneous manifestations of COVID‐19: diagnosis and management

Nicole Seebacher · Julie Kirkham · Saxon D Smith

Previous Issue Volume 216 Issue 11

View more
MJA 216 11 20 June cover
News 20 June 2022 Free

News briefs

Perspectives 20 June 2022 Open Access

Dynamic consent and personalised medicine

Liza Goncharov · Hanna Suominen · Matthew Cook

Perspectives 30 May 2022 Open Access

Returning raw genomic data: rights of research participants and obligations of health care professionals

Jane L Nielsen · Carolyn Johnston · Tracey O'Brien · Vanessa J Tyrrell

Perspectives 23 May 2022 Free

International medical graduates (IMGs) in cul‐de‐sacs: “lost in the labyrinth” revisited?

Neville D Yeomans · Ayaz Chowdhury · Alan Roberts

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.